Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: A case report

被引:3
作者
Kinoshita, Tatsuya [1 ]
Inoue, Hitoshi [1 ]
Kinouchi, Toshiro [1 ]
Kobayashi, Masao [1 ]
Takada, Tsuyoshi [1 ]
Hara, Tsuneo [1 ]
Hatano, Koji [2 ]
Nonomura, Norio [2 ]
机构
[1] Ikeda Municipal Hosp, Dept Urol, Ikeda, Osaka 5638510, Japan
[2] Osaka Univ, Grad Sch Med, Dept Urol, Osaka, Japan
关键词
multi-kinase inhibitor; preoperative; renal cancer; sorafenib; TARGETED THERAPY;
D O I
10.1111/j.1442-2042.2009.02444.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib. Complete resection of the left renal mass measuring 7.2 x 6.6 cm seemed to be difficult at diagnosis because of large renal hilar lymph nodes. With a short period of sorafenib administration, marked shrinkage of the renal mass and lymphadenopathy was observed after the patient experienced fulminant hepatic failure and a severe hand-foot skin reaction. Two-dimensional computed tomography revealed 60%, 78% and 84% reduction in the primary renal tumor, lung metastatic nodules and lymph nodes, respectively. Tumor shrinkage allowed for complete resection of the left kidney and the lymphadenopathy. Pathological findings revealed that over 90% of the renal tumor was substituted by necrotic fibrotic tissue and that the residual neoplastic component was diagnosed as clear cell carcinoma. The lymph nodes that were resected were negative for malignancy. At 6 months after radical nephrectomy, a new computed tomography scan revealed no evidence of disease with the disappearance of lung nodules.
引用
收藏
页码:286 / 288
页数:3
相关论文
共 10 条
[1]   Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma [J].
Akaza, Hideyuki ;
Tsukamoto, Taiji ;
Murai, Masaru ;
Nakajima, Keiko ;
Naito, Seiji .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (10) :755-762
[2]   Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy [J].
Amin, Chirag ;
Wallen, Eric ;
Pruthi, Raj S. ;
Calvo, Benjamin F. ;
Godley, Paul A. ;
Rathmell, W. Kimryn .
UROLOGY, 2008, 72 (04) :864-868
[3]   Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib [J].
Baccala, Angelo, Jr. ;
Hedgepeth, Ryan ;
Kaouk, Jihad ;
Magi-Galluzzi, Christina ;
Gilligan, Timothy ;
Fergany, Amr .
INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (12) :1095-1097
[4]   Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy [J].
Di Silverio, Franco ;
Sciarra, Alessandro ;
Parente, Ulderico ;
Andrea, Alfarone ;
Von Heland, Magnus ;
Panebianco, Valeria ;
Passariello, Roberto .
UROLOGIA INTERNATIONALIS, 2008, 80 (04) :451-453
[5]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[6]   Recent advances in molecular targeted therapy for metastatic renal cell carcinoma [J].
Mizutani, Yoichi .
INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (05) :444-448
[7]   Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma [J].
Rini, BI ;
Small, EJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :1028-1043
[8]  
Schramm C, 2008, AM J GASTROENTEROL, V103, P2162, DOI 10.1111/j.1572-0241.2008.01982_19.x
[9]   Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm [J].
Shuch, Brian ;
Riggs, Stephen B. ;
LaRochelle, Jeff C. ;
Kabbinavar, Fairooz F. ;
Avakian, Raffi ;
Pantuck, Allan J. ;
Patard, Jean-Jacques ;
Belldegrun, Arie S. .
BJU INTERNATIONAL, 2008, 102 (06) :692-696
[10]   BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].
Wilhelm, SM ;
Carter, C ;
Tang, LY ;
Wilkie, D ;
McNabola, A ;
Rong, H ;
Chen, C ;
Zhang, XM ;
Vincent, P ;
McHugh, M ;
Cao, YC ;
Shujath, J ;
Gawlak, S ;
Eveleigh, D ;
Rowley, B ;
Liu, L ;
Adnane, L ;
Lynch, M ;
Auclair, D ;
Taylor, I ;
Gedrich, R ;
Voznesensky, A ;
Riedl, B ;
Post, LE ;
Bollag, G ;
Trail, PA .
CANCER RESEARCH, 2004, 64 (19) :7099-7109